info@marketreportsonchina.com

Investigation Report on China Pranoprofen Market, 2010-2019

Press Release   •   Dec 16, 2015 11:20 IST

Dec., 16, 2015, Mumbai, India: Market Reports on China presents the report, on “Investigation Report on China Pranoprofen Market, 2010-2019”. Pranoprofen develops fast after entering China, sales value rising from CNY 64.04 million in 2013 to CNY 74.39 million in 2014 with a year-on-year growth of 16.2% and CAGR during the period of 2010-2014 reaching 38.7%.

According to the 2013 Health Statistical Bulletin, outpatients totaled 62.8312 million in China in 2013. As computer pervades into work and life, eye disease cases grow by millions each year, which leads to the expansion of ophthalmic drug market. 

Originally discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly known as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen was later developed into eye drop by Senju Pharmaceutical Co., Ltd under the trade name of pranopulin for the treatment of inflammation of outer eye or anterior segment of the eye like blepharitis, conjunctivitis and keratitis. In 1999, pranoprofen eye drop was approved by CFDA to enter the Chinese market for clinical use, followed by product from Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd in 2009 and product of in 2013.

Pranoprofen develops fast after entering China, sales value rising from CNY 64.04 million in 2013 to CNY 74.39 million in 2014 with a year-on-year growth of 16.2% and CAGR during the period of 2010-2014 reaching 38.7%. As computer pervades into work and life, the incidence of eye disease keeps rising, which leads to the vast demand for pranoprofen in China. Currently, pranoprofen in the Chinese market mainly come from the following three enterprises: Senju Pharmaceutical Co., Ltd, Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltd, among which Senju Pharmaceutical Co.,Ltd had the largest market share of 89.38% which dropped from 90.59% in 2013 due to Shandong Haishan Pharmaceutical Co., Ltd and Guangzhou Kangqiao Hanpu Pharmaceutical Co., Ltds entering into the market with sales reaching CNY 66.49 million in 2014. Domestic drug is expected to occupy an increasingly large share in the next few years.

Readers can get at least the following information from this report:
-market size of sodium pranoprofen in China
-competitive landscape of sodium pranoprofen in Chinese market
-price of sodium pranoprofen made by different enterprises in China
-market outlook of sodium pranoprofen in China

The author suggests the following groups of people purchase this report:
- manufacturers of ophthalmic drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact for customized survey service

Table of Contents1 Related Concepts of Pranoprofen
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Pranoprofen in China
2.1 Registration and Supplementary Information of Pranoprofen in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey of Pranoprofen Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

To view a full Executive Summary and Table of Contents, please visit:http://www.marketreportsonchina.com/life-sciences-market-research-reports-17016/investigation-china-pranoprofen.html

Related Reports:http://www.marketreportsonchina.com/market-research-report/life-sciences.html

About Author Bio: Sarah Davis is working with MarketReportsonChina which is a portal where you can access thousands of reports on China starting from Aeronautics to Zinc (A-Z). The website provides market reports on different sectors.

Contact Us
Market Reports on China
Contact No: India: +91.22.27810773
Email: info@marketreportsonchina.com
Website: http://www.marketreportsonchina.com/about.php
Twitter: https://twitter.com/ReportsonChina

<br>